股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | | 1 RMB | | 108,000,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 108,000,000 | RMB | | | 1 RMB | | 108,000,000 | 本月底法定/註冊股本總額： RM ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Charmacy Pharmaceutical Co., Ltd. 創美藥業股份有限公司 （於中華人民共和國註冊成立之股份有限公司） （股份代號：2289） (1)公司秘書資格更新； (2)聯席公司秘書辭任； 及 (3)委任上市規則項下的授權代表之替任人及公司條例項下的授權代表 公司秘書資格更新 兹提述創美藥業股份有限公司（「本公司」）2022 年 4 月 8 日的公告，內容有關 (其中包括) 委任黃慧玲女士（「黃女士」）和姚潔晞女士（「姚女士」）為本公司聯席公司秘書（「聯席 公司秘書」），以及香港聯合交易所有限公司（「聯交所」）就姚女士擔任聯席公司秘書資格 向本公司授予豁免，為期三年，自姚女士獲委任為聯席公司秘書的生效日期（即 2022 年 4 月 8 日）起至 2025 年 4 月 7 日止，豁免本公司嚴格遵守《聯交所證券上市規則》（「上市規 則」）第 3.28 條和第 8.17 條的規定。 本公司 ...

第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，本公司執行董事為姚創龍先生、鄭玉燕女士與張寒孜女士；本公司非執行董事為嚴京斌先生、付征女士與徐飛先 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 創美藥業股份有限公司 | | 股份代號 | 02289 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二五年十二月三十一日止年度之末期股息 | | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 ...

Financial Performance - The group's operating revenue for the year ended December 31, 2025, was RMB 4,384.63 million, a decrease of 1.15% compared to RMB 4,435.46 million in 2024[4] - The net profit for the group was RMB 46.27 million, down 13.16% from RMB 53.28 million in 2024[4] - Basic and diluted earnings per share were RMB 0.4285, compared to RMB 0.4934 in 2024[4] - The total operating revenue for the year ended December 31, 2025, was RMB 4,384,632,090.08, a slight decrease of 1.15% compared to RMB 4,435,460,674.85 in the previous year[13] - The main business income for the same period was RMB 4,329,327,974.14, compared to RMB 4,385,119,653.22 in the previous year, reflecting a decrease of 1.27%[13] - The group reported a total profit of RMB 64.31 million for the year, compared to RMB 71.19 million in 2024[5] - The company's net profit for the year was RMB 64,309,395.22, down from RMB 71,192,252.28 in the previous year, indicating a decline of 9.4%[19] - The company's net profit decreased by 13.16% from RMB 53.28 million in 2024 to RMB 46.27 million in 2025, primarily due to an increase in credit impairment losses[79] Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 3,960.01 million, an increase from RMB 3,456.64 million in 2024[7] - Total liabilities increased to RMB 3,343,644,478.28 as of December 31, 2025, up from RMB 2,837,952,734.34 a year earlier, representing an increase of 17.8%[8] - Current liabilities totaled RMB 3,281,151,870.89, which is an increase of 17.7% from RMB 2,788,603,021.09 in the previous year[8] - The total equity attributable to shareholders was RMB 616,363,855.04 as of December 31, 2025, slightly down from RMB 618,690,947.99 the previous year[8] - The capital debt ratio as of December 31, 2025, is 60.40%, an increase from 51.37%[88] Cash Flow and Working Capital - Cash and cash equivalents increased to RMB 753.60 million from RMB 563.15 million in 2024[7] - Cash and bank deposits increased to RMB 221.54 million in 2025 from RMB 171.79 million in 2024[80] - Current assets net value rose to RMB 279.79 million in 2025 from RMB 241.39 million in 2024, maintaining a current ratio of 1.09[81] - Accounts payable increased by 15.72% to RMB 1,405.28 million in 2025 from RMB 1,214.33 million in 2024, optimizing cash flow management[83] - The company maintained a prudent treasury policy, ensuring a healthy liquidity position throughout the reporting period[84] Dividend and Shareholder Returns - The board proposed a final dividend of RMB 0.30 per share (before tax) for the year ended December 31, 2025[4] - The board of directors proposed a final dividend of RMB 0.30 per share (tax included) for the year ending December 31, 2025, compared to RMB 0.45 per share for 2024[21] - The board recommends a final dividend of RMB 0.30 per share (before tax) for the year ending December 31, 2025, subject to shareholder approval[97] Accounts Receivable and Credit Management - Accounts receivable rose to RMB 1,243.09 million, up from RMB 1,163.24 million in 2024[7] - The total accounts receivable amount is RMB 1,277,436,154.14, with a total bad debt provision of RMB 34,348,759.44, resulting in a provision ratio of 2.69%[27] - The aging analysis shows that accounts receivable within one year amount to RMB 1,157,329,775.69, with a bad debt provision of RMB 4,216,473.13, reflecting a provision ratio of 0.36%[30] - The company has implemented internal credit assessment policies to evaluate potential customers' credit quality before accepting new clients[30] - The company plans to continue reviewing overdue receivables regularly to manage credit risk effectively[30] - The total bad debt provision increased to RMB 34,348,759.44, with a current period provision of RMB 15,428,246.79[31] - The top five accounts receivable amounted to RMB 531,837,758.78, representing 41.63% of the total accounts receivable[34] - The actual write-off of accounts receivable during the period was RMB 421,887.39, with no significant write-offs reported[33] - The company has no actual write-offs of accounts receivable during the reporting period[26] Market and Industry Trends - The pharmaceutical circulation industry in China is projected to reach RMB 2.99 trillion in market size by 2025, with a year-on-year growth of 1.5%[44] - Retail pharmacy sales are expected to reach RMB 587.8 billion in 2025, reflecting a growth of 2.4% year-on-year[43] - The online pharmacy sales are anticipated to grow over 30% year-on-year in the first three quarters of 2025[43] - The concentration of the pharmaceutical wholesale market is high, with the top 100 companies accounting for 75.7% of total sales[44] - The external market size is expected to reach RMB 1.6 trillion by 2029, potentially surpassing the internal market[46] - The outpatient market is expected to see a significant increase, with a potential RMB trillion-level growth space due to reforms like "separation of medicine and treatment" and "prescription outflow" policies[63] Strategic Initiatives and Innovations - The company has established strategic partnerships with leading brands such as "China Resources Sanjiu" and "Hualan Biological" to enhance its marketing ecosystem and improve supply chain efficiency[55] - The company has integrated AI technology into key business areas, achieving over 50% improvement in development efficiency and enhancing operational compliance management[59] - The company aims to expand its third-party pharmaceutical logistics business, providing professional warehousing, logistics, and transportation services to upstream suppliers and downstream customers[69] - The company is focused on enhancing its digital competitiveness through the integration of AI technology, aiming for a comprehensive intelligent supply chain ecosystem[65] - The company plans to enhance its digital transformation by integrating IoT, big data, AI, and automation into the entire pharmaceutical logistics process, aiming to shift from labor-intensive to technology-intensive operations[62] Compliance and Governance - The audit committee has reviewed the financial statements for the year ending December 31, 2025, in conjunction with the management and external auditors[103] - The company has maintained compliance with all applicable corporate governance codes as of December 31, 2025[100] - There are no significant contingent liabilities as of December 31, 2025[95] - There are no significant events requiring disclosure after the reporting period[96]

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 於本通告日期，本公司執行董事為姚創龍先生、鄭玉燕女士與張寒孜女士；本公司非執 行董事為嚴京斌先生、付征女士與徐飛先生；及本公司獨立非執行董事為尹智偉先生、 李漢國先生與關鍵先生（又名關蘇哲）。 董事會會議通告 創美藥業股份有限公司（｢本公司｣）董事會（｢董事會｣）謹此宣佈，董事會會議將於2026 年3月27日（星期五）舉行，藉以（其中包括）審議及批准本公司及其附屬公司截至2025 年12月31日止年度之全年業績及其發佈，並考慮建議派發末期股息（如有）。 承董事會命 創美藥業股份有限公司 嚴京斌 主席 中國汕頭，2026年3月16日 Charmacy Pharmaceutical Co., Ltd. 創美藥業股份有限公司 （於中華人民共和國註冊成立之股份有限公司） （股份代號：2289） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | 本月底法定/註冊股本總額： RMB 108,000,000 備註： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | 1 | RMB | | 108,000,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 108,000,000 | RMB | | 1 | RMB | | 108,000,000 | 本月底法定/註冊股本總額： RM ...

致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 呈交日期: 2026年1月5日 本月底法定/註冊股本總額： RMB 108,000,000 備註： 因本公司於中華人民共和國註冊成立，法定股本制度不適用於本公司。本節所列數字為本公司的註冊股本。 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | | 增加 / 減少 (-) | | ...

Core Viewpoint - Chuangmei Pharmaceutical (02289.HK) has appointed Tianjian as the auditor for the fiscal year ending December 31, 2025, effective from the conclusion of the extraordinary general meeting, with the term lasting until the next annual general meeting [1] Group 1 - Tianjian will replace Shinewing Certified Public Accountants as the company's auditor following the extraordinary general meeting [1]

Core Viewpoint - Chuangmei Pharmaceutical (02289.HK) announced the proposal to abolish the supervisory board and amend the articles of association, which has been approved by shareholders at an extraordinary general meeting [1] Group 1 - The board of directors has resolved to abolish the supervisory board effective from the date of the extraordinary general meeting [1] - The relevant corporate governance rules related to the supervisory board, including the "Rules of Procedure for the Supervisory Board," have been abolished simultaneously [1] - The powers of the supervisory board will be exercised by the audit committee of the board of directors in accordance with the provisions of the "Company Law of China" [1]